Weaver et al. 4 address this need through a series of experiments designed to identify recurrently mutated genes in esophageal adenocarcinoma and determine the stages of neoplastic progression at which they become mutated. They performed whole-genome sequencing of cancer cases in a discovery cohort (n = 22), identifying 26 genes with recurrent mutations for targeted resequencing in an additional 90 cancer cases. Finally, targeted resequencing for this validated gene panel was carried out in 40 non-dysplastic and 39 high-grade dysplastic Barrett's esophagus samples. Remarkably, they observed that many of the so-called driver mutations of esophageal adenocarcinoma were already present in non-dysplastic Barrett's esophagus, expanding upon previous reports by Dulak et al. 10 and Agrawal et al. 11 . In particular, 53% of the non-dysplastic Barrett's esophagus biopsies and 91% of the high-grade dysplastic Barrett's esophagus samples harbored one or more mutations in the panel. The exceptions were SMAD4, which was mutated only in invasive chronic gastroesophageal reflux 5 . Because persons with Barrett's esophagus have about 30-fold higher risk of developing esophageal adenocarcinoma, it is often recommended that they undergo periodic surveillance with endoscopy and multiple biopsies to detect the development of high-grade dysplasia or the presence of an early cancer that can be effectively treated 6 . However, Barrett's esophagus can remain in a relatively quiescent state for many years without becoming malignant; conversely, when it occasionally does 'go bad' , this can happen quite quickly 7 . Consequently, the effectiveness of surveillance for reducing mortality is a topic of much debate, especially when costs are taken into account 8, 9 . Identifying robust biomarkers of neoplastic progression risk would be helpful in directing primary and secondary prevention efforts to those most likely to benefit while permitting the large majority of those unlikely to develop esophageal adenocarcinoma to avoid subsequent procedures, risks, costs and worry.
In 2012, more than 450,000 new cases of esophageal cancer are estimated to have occurred worldwide, making this cancer the eighth most common 1 . In less developed regions, squamous cell carcinoma is by far the most common histological type. In contrast, the United States has seen a remarkable 500% increase in the incidence of adenocarcinoma, transforming it from a relative rarity in the 1970s to the most common type of esophageal cancer today; similar increases in incidence have been documented in much of Western Europe and Australia 2 . Unfortunately, the vast majority of affected individuals are not diagnosed with esophageal cancer until a late stage, and, regardless of histological tumor type, most succumb within a year of diagnosis. Thus, prevention and early detection must remain society's 'plan A' for combating this disease 3 . The research reported by Rebecca Fitzgerald and colleagues on page 837 is a relatively rare example of a study in which both a cancer and its key precursor lesion have been sequenced, and this study contributes in a number of useful ways to prevention efforts as well as to understanding of the timing and frequency of somatic mutations in neoplastic progression in the esophagus 4 .
Ordering of genomic abnormalities
Most esophageal adenocarcinomas arise in metaplastic epithelium, termed Barrett's esophagus, usually as a consequence of
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The genetic determinants of progression from premalignant Barrett's esophagus to esophageal adenocarcinoma are not known. a new study reports genomic sequence analyses of this progression and uses the insights gained to identify high-risk Barrett's esophagus in a new non-endoscopic test. cancers, and TP53, which was mutated only rarely in non-dysplastic Barrett's esophagus (2.5%) but frequently in high-grade dysplasia (72%) and invasive cancer samples (69%). It should be noted that the relatively small size of the discovery cohort and the observation that additional genes varied in their mutation frequency between stages, but at a level of statistical significance that did not survive correction for multiple testing, suggest that increased sample size might lead to the identification of additional genes useful in discrimination.
Opportunities for translation
Although the presence of mutated TP53 in high-grade dysplasia and its predictiveness of subsequent esophageal adenocarcinoma have been known for a number of years 12 , a particularly exciting aspect of the research reported by Weaver et al. 4 relates to the application of this knowledge to a developing nonendoscopic clinical test-the Cytosponge 13 . This is a dissolvable capsule that contains a compressed mesh attached to a string; after the capsule is swallowed and allowed to dissolve in the stomach, the expanded mesh is withdrawn. The authors established the ability of the Cytosponge to collect cells in which TP53 mutations could be reliably detected, despite the low and variable allele fractions for mutant DNA (ranging from <1% to 36%). They further demonstrated the ability of this approach to identify the presence of high-grade dysplasia with 86% sensitivity (19 mutations detected in 22 individuals with high-grade dysplastic Barrett's esophagus) and 100% specificity (0 mutations detected in 67 individuals with non-dysplastic Barrett's esophagus or with no Barrett's esophagus).
How might this approach be translated into improved clinical care? In the current paradigm, there is a substantial 'risk gap' between the large number of persons in the general population who may have recurrent symptoms of gastroesophageal reflux and/or other risk factors for esophageal adenocarcinoma and the much smaller number in whom relevant mutations and other genomic abnormalities have already occurred, marking these individuals as having significant absolute risk of developing the malignancy. Performing invasive endoscopy in (potentially) all persons with recurrent reflux symptoms, who comprise about 20% of the adult population, is an expensive proposition with very low yield. A non-endoscopic test, such as use of the Cytosponge with TP53 mutation assays, would provide the primary care provider with an important tool to bridge this risk gap (Fig. 1) . For example, the officebased test could be offered only to selected individuals, such as those considered to be at elevated risk on the basis of a panel of known risk factors and blood-based biomarkers, and only those with evidence of TP53 mutations would be referred to secondary care providers. This strategy would potentially result in many fewer individuals undergoing endoscopy, but those who did would be at substantially higher risk, representing an appropriate population for more invasive tests and intensive prevention and treatment efforts. This technology has not yet matured but is getting closer. Inexpensive and reliable assays available outside of a research setting are needed, in concert with prospective studies and clinical trials. The inclusion of endpoints other than high-grade dysplasia also should be considered 5 . However, as recent simulation modeling predicts that the incidence of esophageal adenocarcinoma will continue to increase for two more decades, with a cumulative number of cause-specific deaths of approximately 160,000 in the United States alone 14 , progress in this area cannot come too quickly.
expected that the 1000 bull genomes project will have a major impact on how we select cattle and how much genetic progress we can achieve.
From pedigree-to genetic-based selection During the last decade, cattle breeding has undergone a once-in-a-lifetime revolution. Since 2005, more than 750,000 animals have been genotyped with genome-wide SNP arrays. This information has been used to predict representing four major breeds and including elite sires that have contributed a substantial proportion of the chromosomes segregating in the present population. Variant calling uncovered 26.7 million SNPs and 1.6 million insertions/deletions (indels), 79% of which are new. Concerns are often voiced that intense selection in animals and plants may lead to potentially detrimental erosion of domestic diversity. Surprisingly, the nucleotide diversity of present-day domestic cattle appears to be larger than that found in humans. It is A reference sequence for the bovine genome was first reported in 2009 (ref. 1). Now, on page 858 of this issue, Ben Hayes and colleagues 2 describe the generation and analysis of the whole-genome sequences of 234 bulls Towards sequence-based genomic selection of cattle
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an international effort, the 1000 bull genomes project, aims to resequence the genomes of a large number of key ancestor bulls of the most important domestic cattle breeds. a new study reports on the first results of this important initiative based on the analysis of the first 234 bovine whole-genome sequences.
